Exhibit 99.1

          TRANSGENOMIC, INC. ANNOUNCES APPOINTMENT OF NEW BOARD MEMBER

    OMAHA, Neb., April 18 /PRNewswire-FirstCall/ -- Transgenomic, Inc.
(OTC Bulletin Board: TBIO) announced that it has appointed Frank R. Witney,
Ph.D., to its Board of Directors.  Dr. Witney is currently President, CEO and
a member of the Board of Directors of Panomics Inc.  Panomics develops and
markets products for single and multiplex gene and protein expression analysis
from cell and tissue specimens, as well as cell-based assays.  Dr. Witney is
currently serving as a board member for Applied Precision, a privately held
company that serves the semiconductor process and measurement systems and life
science imaging market.  Dr. Witney's professional and academic interests have
been focused on the biotech and life sciences market throughout his career.
Prior to his current position, he was President of PerkinElmer's Drug
Discovery Business Unit and before that he served as President and COO of
Packard BioSciences.

    In making this announcement, Transgenomic President and CEO, Craig Tuttle,
stated, "We are very excited to have Dr. Witney join the Company's Board of
Directors.  Dr. Witney has a tremendous reputation in the life sciences
marketplace and as a successful biotech entrepreneur.  He brings a detailed
understanding of genomics and gene regulation for drug targeting and
therapeutic research to our Board.  He will provide significant leadership to
the Company as we expand our own genetic testing services laboratory business
in the cancer discovery area."  Mr. Tuttle further noted, "We are entering an
exciting time at Transgenomic where we are applying our many years of mutation
discovery and technical expertise to expand our product and service offerings
and drive the company's growth.  Adding Dr. Witney to the Board will aid us
significantly in achieving these goals."

    About Transgenomic:  A decade of discovery 1997 - 2007

    Transgenomic is a global biotechnology company that provides unique
products and services for automated high sensitivity genetic variation and
mutation analysis.  Their offerings include systems, products, discovery and
laboratory testing services to the academic and medical research, clinical
laboratory and pharmaceutical markets in the fields of pharmacogenomics and
personalized medicine.  Specific offerings include WAVE(R) DHPLC Systems,
related consumables and assay kits, cytogenetics automated systems, and
Transgenomic Discovery and CLIA Lab Services.  Transgenomic Discovery and Lab
Services utilize their technology and expertise to provide a menu of mutation
scanning tests for over 700 cancer-associated genes and more than 60 validated
diagnostic tests to meet the needs of pharmaceutical and biotech companies,
research and clinical laboratories, physicians and patients.  For more
information about the innovative systems, products and services offered by
Transgenomic, please visit:  www.transgenomic.com.

    Transgenomic Cautionary Statements

    Certain statements in this press release constitute "forward-looking
statements" of Transgenomic within the meaning of the Private Securities
Litigation Reform Act of 1995, which involve known and unknown risks,
uncertainties and other factors that may cause our actual results to be
materially different from any future results, performance or achievements
expressed or implied by such statements.  Forward-looking statements include,
but are not limited to, those with respect to management's current views and
estimates of future economic circumstances, industry conditions, company
performance and financial results, including the ability of the Company to
grow its involvement in the diagnostic products and services markets.  The
known risks, uncertainties and other factors affecting these forward-looking
statements are described from time to time in Transgenomic's reports to the
Securities and Exchange Commission.  Any change in such factors, risks and
uncertainties may cause the actual results, events and performance to differ
materially from those referred to in such statements.  Accordingly, the
company claims the protection of the safe harbor for forward-looking
statements contained in the Private Securities Litigation Reform Act of 1995
with respect to all statements contained in this press release.  All
information in this press release is as of the date of the release and
Transgenomic does not undertake any duty to update this information, including
any forward-looking statements, unless required by law.

SOURCE  Transgenomic, Inc.
    -0-                             04/18/2007
    /CONTACT:  Debra Schneider, Chief Financial Officer of Transgenomic, Inc.,
+1-402-452-5400, or fax, +1-402-452-5461, investorrelations@transgenomic.com/
    /Web site:  http://www.transgenomic.com /